<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0122509</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-40106</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>miR-185 Plays an Anti-Hypertrophic Role in the Heart via Multiple Targets in the Calcium-Signaling Pathways</article-title>
<alt-title alt-title-type="running-head">miR-185 Is Anti-Hypertrophic in the Heart</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Jin Ock</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Song</surname>
<given-names>Dong Woo</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kwon</surname>
<given-names>Eun Jeong</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hong</surname>
<given-names>Seong-Eui</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Song</surname>
<given-names>Hong Ki</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Min</surname>
<given-names>Choon Kee</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kim</surname>
<given-names>Do Han</given-names>
</name>
<xref rid="cor001" ref-type="corresp">*</xref>
<xref rid="aff001" ref-type="aff"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Dulak</surname>
<given-names>Jozef</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, POLAND</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: JOK DHK. Performed the experiments: JOK DWS EJK SH HKS CKM. Analyzed the data: JOK DHK. Contributed reagents/materials/analysis tools: JOK SH HKS. Wrote the paper: JOK DHK.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">dhkim@gist.ac.kr</email> (DHK)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>3</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<elocation-id>e0122509</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>9</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>2</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Kim et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0122509" xlink:type="simple"/>
<abstract>
<p>MicroRNA (miRNA) is an endogenous non-coding RNA species that either inhibits RNA translation or promotes degradation of target mRNAs. miRNAs often regulate cellular signaling by targeting multiple genes within the pathways. In the present study, using Gene Set Analysis, a useful bioinformatics tool to identify miRNAs with multiple target genes in the same pathways, we identified <italic>miR-185</italic> as a key candidate regulator of cardiac hypertrophy. Using a mouse model, we found that <italic>miR-185</italic> was significantly down-regulated in myocardial cells during cardiac hypertrophy induced by transverse aortic constriction. To confirm that <italic>miR-185</italic> is an anti-hypertrophic miRNA, genetic manipulation studies such as overexpression and knock-down of <italic>miR-185</italic> in neonatal rat ventricular myocytes were conducted. The results showed that up-regulation of <italic>miR-185</italic> led to anti-hypertrophic effects, while down-regulation led to pro-hypertrophic effects, suggesting that <italic>miR-185</italic> has an anti-hypertrophic role in the heart. Our study further identified <italic>Camk2d</italic>, <italic>Ncx1</italic>, and <italic>Nfatc3</italic> as direct targets of <italic>miR-185</italic>. The activity of Nuclear Factor of Activated T-cell (NFAT) and calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ) was negatively regulated by <italic>miR-185</italic> as assessed by NFAT-luciferase activity and western blotting. The expression of phospho-phospholamban (Thr-17), a marker of CaMKIIδ activity, was also significantly reduced by <italic>miR-185</italic>. In conclusion, <italic>miR-185</italic> effectively blocked cardiac hypertrophy signaling through multiple targets, rendering it a potential drug target for diseases such as heart failure.</p>
</abstract>
<funding-group>
<funding-statement>This work was supported by the 2014 GIST Systems Biology Infrastructure Establishment Grant and the National Research Foundation of Korea (NRF) grants funded by the Korea Government, the Ministry of Science, ICT &amp; Future Planning (2013M3A9A7046297). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="0"/>
<page-count count="17"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Cardiac hypertrophy is an adaptive response to diverse extrinsic and intrinsic stimuli, which is accompanied by enlarged cardiomyocyte size, highly organized sarcomeres, increased protein synthesis and re-activation of fetal genes [<xref rid="pone.0122509.ref001" ref-type="bibr">1</xref>]. The hypertrophic gene program is complex and multifactorial, and it is continuously influenced by regulatory actions of genetic molecules such as miRNAs and mRNAs [<xref rid="pone.0122509.ref002" ref-type="bibr">2</xref>–<xref rid="pone.0122509.ref004" ref-type="bibr">4</xref>]. Although cardiac hypertrophy is initially compensatory to diverse stimuli, prolonged cardiac hypertrophy eventually leads to congestive heart failure and sudden death [<xref rid="pone.0122509.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0122509.ref006" ref-type="bibr">6</xref>].</p>
<p>MicroRNA (miRNA) is a recently discovered species of non-coding RNAs that regulates target gene expression post-transcriptionally [<xref rid="pone.0122509.ref007" ref-type="bibr">7</xref>]. A number of recent experimental data have suggested that individual miRNAs modulate the expression of a set of genes that often share common signal transduction pathways in heart [<xref rid="pone.0122509.ref008" ref-type="bibr">8</xref>]. For example, <italic>miR-378</italic> targets the 3′-UTR of <italic>Igf1r</italic>, <italic>Grb2</italic>, <italic>Ksr1</italic>, and <italic>Mapk1</italic> to regulate the mitogen-activated protein kinase (MAPK) pathway [<xref rid="pone.0122509.ref009" ref-type="bibr">9</xref>]. <italic>miR-133</italic> protects the heart from apoptosis through direct repression of multiple key components along β1-adrenergic receptor signal transduction, such as <italic>adbr1</italic>, <italic>adcy6</italic>, <italic>prkacb</italic>, and <italic>epac</italic> [<xref rid="pone.0122509.ref010" ref-type="bibr">10</xref>]. Thus far, numerous miRNAs showing differential expression during pathological cardiac hypertrophy have been described [<xref rid="pone.0122509.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0122509.ref012" ref-type="bibr">12</xref>], but whether those documented miRNAs are able to interact with multiple targets in the hypertrophic processes still not been systematically studied.</p>
<p>Gene Set Analysis (GSA) is a useful bioinformatics tool developed to identify signaling pathways for certain biological phenomena, by performing statistical enrichment tests for pre-defined gene sets. It is especially useful to infer functions of miRNAs, since numerous miRNA targets can be grouped into signaling pathways, allowing for interpretation of their functions.</p>
<p>In the present study, we performed cardiac specific GSA to identify specific miRNAs whose targets are significantly enriched in the hypertrophic signaling pathways, thereby efficiently regulating the gene programs. Among 18 candidate miRNAs, we found that <italic>miR-185</italic> plays a significant anti-hypertrophic role in the heart through multiple targets in Ca<sup>2+</sup>-signaling. We propose that <italic>miR-185</italic> is a potential drug target for diseases such as heart failure.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials And Methods</title>
<sec id="sec003">
<title>Aortic banding</title>
<p>The transverse aortic constriction (TAC) operation was performed on 8-week-old male C57BL/6 mice under anesthesia by intraperitoneal injection of avertin, 2–2–2 tribromoethanol (Sigma-Aldrich) dissolved in tert-amyl alcohol (Sigma-Aldrich). The operation procedure was followed as previously described [<xref rid="pone.0122509.ref013" ref-type="bibr">13</xref>]. The mice were anesthetized, and then were ventilated with a tidal volume of 0.1 mL and a respiratory rate of 120 breaths per min (Harvard Apparatus). The chest was opened and the transverse aortic arch was tied using a 27-gauge needle to give same space to aorta. Sham-operated mice were treated identically except the aorta was not ligated. On days 1, 3, 7, 14, 21, and 35 after the operation, mice were sacrificed by cervical dislocation, and hearts were removed, and weighted promptly.</p>
</sec>
<sec id="sec004">
<title>Cell culture and transfection</title>
<p>Neonatal rat ventricular myocytes (NRVMs) and neonatal rat cardiac fibroblasts were isolated using neonatal cardiomyocyte isolation system (Worthington), according to the manufacturer’s instructions. Ten or more hearts were removed from 1- to 3-day-old Sprague-Dawley rat pups, finely minced, and digested with trypsin overnight at 4°C. The following day, the heart tissue was dissociated by collagenase treatment (300 units/ml) at 37°C for 45 min. Cardiomyocytes and cardiac fibroblasts were separated using selective attachment procedures and were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (GIBCO). Cardiac fibroblasts were grown to confluence and subsequently passaged by trypsin. Quantitative real-time PCR (qRT-PCR) analysis of <italic>miR-185</italic> expression was conducted on cardiac fibroblasts at <italic>passage</italic> 3. Cardiomyocytes were seeded at a density of 0.9 million cells per dish onto 1% gelatin-coated 60-mm (Corning) culture dishes and cultured overnight in DMEM supplemented with 10% FBS, 1% antibiotics (WelGENE), 0.1 mmol/L BrdU at 37°C in a humidified incubator with 5% CO<sub>2</sub>. The following day, they were placed on serum-free medium without antibiotics for 24 h prior to miRNA transfection. Cells were then transfected with 15 nmol/L miRIDIAN microRNA mimic rno-miR-185, miRIDIAN microRNA mimic negative control #1 (NC), 100 nmol/L of miRIDIAN microRNA hairpin inhibitor rno-miR-185, and miRIDIAN microRNA hairpin inhibitor negative control #2 (NC inhibitor) using DharmaFECT-3 reagent (all obtained from Dharmacon) according to the manufacturer’s instructions. After 24 h, NRVMs were stimulated with hypertrophic reagent, endothelin-1 (ET-1, 10 nmol/L, Sigma-Aldrich) for 48 h, and cells were harvested for RNA isolation, immunocytochemistry, or western blot analysis. ET-1 was solubilized in oxygen free water to minimize oxidation.</p>
</sec>
<sec id="sec005">
<title>Total RNA preparation and reverse transcription</title>
<p>Total RNA and mature miRNAs were isolated from whole hearts, NRVMs, or cardiac fibroblasts using a miRNeasy Mini kit (Qiagen), and reverse transcribed with a miScript Reverse Transcription Kit (Qiagen) in accordance with the manufacturer’s instructions.</p>
</sec>
<sec id="sec006">
<title>qRT-PCR</title>
<p>qRT-PCR for <italic>miR-185</italic> targets and hypertrophic markers was performed with primers listed in Table B in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>, using SYBR green dye (Kapa Biosystem) and StepOne Plus Real Time PCR System (Applied Biosystems). miRNA-specific qRT-PCR in tissue or isolated cells was done using miScript SYBR Green PCR Kit (Qiagen) according to the manufacturer’s protocol, with miScript Primer Assay (for <italic>miR-185</italic>; Qiagen). The expression of the mRNAs was normalized to 18S rRNA and the level of <italic>miR-185</italic> was normalized to <italic>U6</italic> small RNA using the Hs_RNU6B_2 miScript Primer Assay (Qiagen). All reactions were performed in triplicate.</p>
</sec>
<sec id="sec007">
<title>Immunostaining and cell surface area measurements</title>
<p>NRVMs were grown on 1% gelatin coated-glass coverslips (18-mm diameter). The cells then were transfected with miRNA mimic or hairpin inhibitor for <italic>miR-185</italic>, or for the negative control, with DharmaFECT-3 reagent. Twenty four hours after transfection, cells were stimulated with 10 nmol/L ET-1 for another 48 h to induce cardiac hypertrophy. Next, cells were fixed with 4% paraformaldehyde for 15 min at RT, washed 3 times with PBS, permeabilized with 0.1% Triton X-100, and blocked with 10% bovine serum albumin (Sigma-Aldrich) in PBS for 30 min. The cells then were incubated with anti-α-actinin antibody (Sigma-Aldrich) in blocking buffer O/N at 4°C, rinsed six times with PBS, incubated with secondary antibody (Alexa 594-conjugated anti-mouse IgG antibody, Molecular Probe) in the blocking buffer for 2 h at 37°C, rinsed three times with PBS, and mounted. The slides were examined with an LSM 700 confocal laser scanning microscope (Carl Zeiss).</p>
</sec>
<sec id="sec008">
<title>Luciferase reporter assay</title>
<p>For miRNA target identification, we constructed reporter vectors bearing the exact target sites for <italic>miR-185</italic>. We obtained 250–350 base pairs of the 3′-UTRs of mouse target mRNAs by PCR amplification. The mutant constructs were generated by introducing mutations into the putative <italic>miR-185</italic>-binding sites by standard overlap PCR using mutagenic primers. All constructs were sequenced to confirm that the desired mutations had been obtained. To form a chimeric plasmid, the amplified products were inserted into the multiple cloning sites immediately downstream of the luciferase gene via the NheI and XhoI restriction sites in the pmirGLO Dual-Luciferase miRNA target expression vector (Promega). Then, human embryonic kidney (HEK)-293 cells were transfected using Lipofectamin LTX (Invitrogen) with 0.5 μg of the pmirGLO chimeric plasmid containing wild-type (WT) or mutant 3′-UTR along with the NC or <italic>miR-185</italic> mimic (Dharmacon) at a final concentration of 15 nmol/L. Seventy-two hours after transfection, cells were lysed and the reporter activity was detected with the Dual-Luciferase Reporter Assay System (Promega) on the Victor X3 multilabel plate reader (PerkinElmer, Waltham, MA). Firefly luciferase activity was normalized to the corresponding <italic>Renilla</italic> luciferase activity. For all experiments, transfection took place 24 h after starvation of cells in serum-free medium. The normalized luciferase activity relative to control group was used to demonstrate the alterations of mRNA transcription.</p>
<p>For measuring Nuclear Factor of Activated T-cell (NFAT) activity, NFAT-luciferase assays were performed as described previously with minor modifications [<xref rid="pone.0122509.ref014" ref-type="bibr">14</xref>]. Briefly, 9xNFAT-luciferase reporter plasmid and pRL-TK containing the <italic>Renilla</italic> luciferase gene were cotransfected into NRVMs 24 h after transfection of NC inhibitor or <italic>miR-185</italic> inhibitor. The next day, NRVMs were stimulated with ET-1 (10 nmol/L) for 24 h. A luciferase reporter plasmid driven by nine NFAT binding sites was kindly provided by Dr. Jeffery D. Molkentin (University of Cincinnati, Ohio).</p>
</sec>
<sec id="sec009">
<title>Western blotting</title>
<p>Protein samples were prepared from freshly isolated NRVMs using ice-cold lysis buffer supplemented with the protease inhibitor cocktail (Roche) and the phosphatase inhibitor cocktail (PhosSTOP, Roche). Protein concentrations were determined using the BCA protein assay kit (Pierce). Samples were subsequently separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes followed by blocking with 5% skim milk (BD Science) or 5% BSA (Sigma-Aldrich) in TBST (0.1% Tween 20 in Tris-buffered saline; 137 mmol/L NaCl and 20 mmol/L Tris/HCl, pH 7.4) for 1 h at room temperature. Membranes were then incubated overnight at 4°C with the following antibodies: anti-CaMKIIδ (Santa Cruz), anti-phospho-CaMKIIδ (Cell Signaling), anti-NCX1 (Abcam), anti-NFATC3 (Santa Cruz), anti-p-NFATC3 (Santa Cruz), anti-phospholamban (Thermo Fisher Scientific), anti-phospho-phospholamban (Thr-17; Badrilla), anti-α-tubulin (Santa Cruz), and anti-GAPDH (homemade). After primary antibody incubation, membranes were washed with TBST and further incubated with the appropriate horseradish peroxidase-conjugated (HRP-conjugated) secondary antibody at room temperature for 1 h. The western blot signal was detected using an ImageQuant LAS 4000 mini (GE Healthcare Bio-Sciences AB) and a SuperSignal West Pico Chemiluminescence Kit (Thermo Fisher Scientific). The intensities of the protein bands were analyzed by ImageJ software (NIH).</p>
</sec>
<sec id="sec010">
<title>Ethical statement</title>
<p>All animal experiments were approved by the Gwangju Institute of Science and Technology Animal Care and Use Committee (Permit number: GIST2012–15).</p>
</sec>
<sec id="sec011">
<title>Statistical analysis</title>
<p>We used the Student’s unpaired <italic>t</italic>-test for comparisons between the two groups. Data are shown as mean ± SEM from more than 3 independent experiments conducted on separate days. <italic>P</italic>-values of *<italic>P</italic>&lt;0.05 and **<italic>P</italic>&lt;0.01 were considered statistically significant.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Identification of candidate miRNAs associated with the cardiac hypertrophy signaling pathway</title>
<p>In the present study, we developed a novel framework to infer functions of cardiac miRNAs by employing 143 consensus cardiac-expressed miRNAs and 10,451 cardiac-expressed mRNAs (Figure A in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref> and <xref rid="pone.0122509.s002" ref-type="supplementary-material">S1 Table</xref>). To strengthen our prediction power and infer more fundamental mechanisms of regulation by miRNA, we took into account common miRNA:mRNA complementarity in human and mouse, and context score percentile (CSP) of seed sites during the enrichment test. By doing so, we derived 902 miRNA-pathway connections in total (<xref rid="pone.0122509.s003" ref-type="supplementary-material">S2 Table</xref>). We explored the ability of our method to identify hypertrophy-modulating miRNAs by testing several hypertrophy-related gene sets extracted from databases. Strikingly, our results showed strong enrichment of targets of 18 miRNAs in various cardiac hypertrophy signaling pathways, including earlier investigations for the regulation of cardiac hypertrophy by miRNAs (Figure B in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). For example, it has been reported that <italic>miR-221</italic> [<xref rid="pone.0122509.ref015" ref-type="bibr">15</xref>], <italic>miR-199a/b</italic> [<xref rid="pone.0122509.ref016" ref-type="bibr">16</xref>][<xref rid="pone.0122509.ref017" ref-type="bibr">17</xref>], <italic>miR-27b</italic> [<xref rid="pone.0122509.ref018" ref-type="bibr">18</xref>], <italic>miR-195</italic> [<xref rid="pone.0122509.ref011" ref-type="bibr">11</xref>] and <italic>miR-34a/b/c</italic> [<xref rid="pone.0122509.ref019" ref-type="bibr">19</xref>] positively regulate cardiac hypertrophy, while <italic>miR-378</italic> [<xref rid="pone.0122509.ref009" ref-type="bibr">9</xref>], <italic>miR-29</italic> [<xref rid="pone.0122509.ref020" ref-type="bibr">20</xref>], <italic>miR-150</italic> [<xref rid="pone.0122509.ref011" ref-type="bibr">11</xref>], <italic>miR-223</italic> [<xref rid="pone.0122509.ref021" ref-type="bibr">21</xref>] and <italic>miR-1</italic> [<xref rid="pone.0122509.ref022" ref-type="bibr">22</xref>] negatively regulate cardiac hypertrophy. On the other hand, <italic>miR-99a</italic> [<xref rid="pone.0122509.ref023" ref-type="bibr">23</xref>] and <italic>miR-486</italic> [<xref rid="pone.0122509.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0122509.ref025" ref-type="bibr">25</xref>] are involved in myocardial remodeling through the regulation of different types of signaling pathways. Moreover, we found that each predicted miRNA family has multiple high-score targets in the cardiac hypertrophy signaling pathway (<xref rid="pone.0122509.s003" ref-type="supplementary-material">S2 Table</xref>), of which many already have been validated as direct targets of the corresponding miRNAs <italic>in vitro</italic>. Figure B in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref> is a comparison of miRNA target enrichment results, showing a large overlap among the predicted miRNA-hypertrophy pathway associations. The integrated cardiac hypertrophy network (Figure C in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>) suggests potential interplay among the 18 miRNAs in the regulation of cardiac hypertrophy signaling pathway through highly intricate co-targeting.</p>
</sec>
<sec id="sec014">
<title><italic>miR-185</italic> negatively regulates cardiac hypertrophy</title>
<p>Among the identified 18 miRNAs through GSA, six were previously unknown. We attempted to verify the effects of these six miRNAs (<italic>miR-185</italic>, <italic>miR-139–5p</italic>, <italic>miR-374</italic>, <italic>miR-324–5p</italic>, <italic>miR-153</italic>, and <italic>miR-141</italic>) on myocardial hypertrophy. qRT-PCR analysis of the hypertrophy markers ANF and BNP in transfected NRVMs showed that <italic>miR-139–5p</italic> and <italic>miR-374</italic> mimics markedly increased the expression of ANF and BNP, while <italic>miR-324–5p</italic>, <italic>miR-153</italic>, and <italic>miR-141</italic> mimics did not significantly affect the expression (unpublished data). However, transfection of <italic>miR-185</italic> mimic significantly reduced the mRNA expression of ANF and BNP in NRVMs (<xref rid="pone.0122509.g001" ref-type="fig">Fig. 1C and 1D</xref>).</p>
<fig id="pone.0122509.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g001</object-id>
<label>Fig 1</label>
<caption>
<title><italic>miR-185</italic> negatively regulate cardiomyocyte hypertrophy.</title>
<p> (A, E) Microscopic images of immunofluorescence staining of NRVMs with α-actinin antibody. Twenty-four hours after transfection with <italic>miR-185</italic> (15 nmol/L) (A) or <italic>miR-185</italic> inhibitor (100 nmol/L) (E), NRVMs were stimulated with ET-1 for 48 h. Scale bar = 50 μm. (B, F) Cell surface areas of NRVMs measured using Image J software (N = 50 cells for each group). Untreated NRVMs served as controls. (C, D, G, H) qRT-PCR analysis of hypertrophic marker genes after transfection of <italic>miR-185</italic> mimic (C, D) or <italic>miR-185</italic> inhibitor (G, H) in the presence or absence of ET-1 (10 nmol/L). All data are expressed as mean ± SEM; *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.001; N = 4.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g001" position="float" xlink:type="simple"/>
</fig>
<p><italic>miR-185</italic> was selected for further study due to the following reasons: First, <italic>miR-185</italic> was consistently found across four different cardiac hypertrophy signaling pathways. Second, <italic>miR-185</italic> is expressed primarily in the heart, brain and kidney [<xref rid="pone.0122509.ref026" ref-type="bibr">26</xref>], suggesting a potential role in these tissues. Third, <italic>miR-185</italic> is differentially expressed in the heart of pressure overload-induced cardiac hypertrophy models [<xref rid="pone.0122509.ref012" ref-type="bibr">12</xref>]. Finally, <italic>miR-185</italic> has 22 high score targets in cardiac hypertrophy signaling pathway, as determined by cross-species target predictions (Figure B in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>).</p>
<p>We first established a hypertrophy animal model by performing a severe TAC for 1, 3, 7, 14, 21, and 35 days. In this model, cardiac hypertrophy gradually developed and reached a peak on day 21 after TAC (Figure D in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). To determine the level of <italic>miR-185</italic> during the progression of cardiac hypertrophy, we carried out qRT-PCR analysis. Consistent with the previous report [<xref rid="pone.0122509.ref012" ref-type="bibr">12</xref>], we found that the expression of <italic>miR-185</italic> was dramatically down-regulated after TAC, reached a minimal level on day 7 (Figure D in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). The result suggests that <italic>miR-185</italic> may be a critical, quick-responder, regulating cardiac hypertrophy in response to increased biomechanical stress. We also found that the level of <italic>miR-185</italic> is approximately 2 fold higher in cardiomyocytes than cardiac fibroblasts, emphasizing the possible involvement of <italic>miR-185</italic> in cardiomyocyte hypertrophy (Figure D in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>).</p>
<p>To investigate the role of <italic>miR-185</italic> in cardiac hypertrophy, we transfected NRVMs with miRNA mimic or inhibitor of <italic>miR-185</italic>, followed by ET-1 stimulation. We found that transfection of <italic>miR-185</italic> reduced ET-1-induced cardiomyocytes hypertrophy, as assessed by the cell surface area measurement (<xref rid="pone.0122509.g001" ref-type="fig">Fig. 1A and 1B</xref>) and hypertrophic markers, including <italic>ANF</italic> and <italic>BNP</italic> (<xref rid="pone.0122509.g001" ref-type="fig">Fig. 1C and 1D</xref>). To further substantiate the inhibitory role of <italic>miR-185</italic>, we performed knockdown experiments. Treatment with a specific inhibitor for <italic>miR-185</italic> markedly down-regulated <italic>miR-185</italic> expression (Figure E in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>) and accelerated ET-1 induced cardiomyocytes hypertrophy, as shown in <xref rid="pone.0122509.g001" ref-type="fig">Figs. 1E-1H</xref>. The expression of <italic>miR-185</italic>, however, is not regulated by ET-1 itself (Figure F in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). Similar anti-hypertrophic effects were observed when NRVMs were stimulated with other hypertrophic agents, such as isoproterenol (ISO, 10 μM) and phenylephrine (PE, 100 μM), after transfection of <italic>miR-185</italic>. As shown in Figure G in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>, over-expression of <italic>miR-185</italic> significantly inhibited ISO- or PE-induced cardiomyocyte hypertrophy as assessed by cell surface area and hypertrophic marker gene expressions. Collectively, the results indicate that <italic>miR-185</italic> negatively regulates cardiac hypertrophy.</p>
</sec>
<sec id="sec015">
<title><italic>miR-185</italic> directly targets multiple key components in the calcium-activated hypertrophic signaling pathway</title>
<p>We next screened for components in the cardiac hypertrophy signaling cascade that are controlled by <italic>miR-185</italic>. Several high score predicted targets were chosen for validation as key mediators of cardiac hypertrophy based on GSA (Figure B in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). To confirm these target predictions, we transfected <italic>miR-185</italic> into NRVMs and determined whether endogenous levels of those target genes were down-regulated. The results showed that both mRNA and protein expression levels of calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ), Na<sup>+</sup>-Ca<sup>2+</sup> exchanger gene (NCX1/SLC8A1), and NFATC3 were significantly repressed by <italic>miR-185</italic> compared with expression in the controls (<xref rid="pone.0122509.g002" ref-type="fig">Fig. 2A-F</xref>).</p>
<fig id="pone.0122509.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g002</object-id>
<label>Fig 2</label>
<caption>
<title><italic>miR-185</italic> regulates the expression of CaMKIIδ, NCX1, and NFATC3 in cultured NRVMs.</title>
<p>(A-C) qRT-PCR analyses of <italic>Camk2d</italic>, <italic>Ncx1</italic> and <italic>Nfatc3</italic> expression after transfection with <italic>miR-185</italic> or NC. (D-F) <italic>miR-185</italic> transfected NRVMs were lysed and analyzed by western blotting using antibodies against the proteins of interest. GAPDH or α-tubulin was used as a loading control. Representative western blots (upper) and quantified western blots (bottom). Data represent the mean ± SEM; *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.001, N = 4.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g002" position="float" xlink:type="simple"/>
</fig>
<p>Next, we determined whether <italic>Camk2d</italic>, <italic>Ncx1</italic>, and <italic>Nfatc3</italic> are the direct targets of <italic>miR-185</italic>. While <italic>Nfatc3</italic> harbors a single binding site for <italic>miR-185</italic> in the 3′-UTR (<xref rid="pone.0122509.g003" ref-type="fig">Fig. 3C</xref>), there are multiple putative binding sites in the 3′-UTRs of <italic>Camk2d</italic> and <italic>Ncx1</italic> in mouse (<xref rid="pone.0122509.g003" ref-type="fig">Fig. 3B and 3D</xref>). To critically examine the interactions between <italic>miR-185</italic> and the putative targets, we measured the activity of the luciferase reporter when linked to either the WT or mutant 3′-UTR of each target (<xref rid="pone.0122509.g003" ref-type="fig">Fig. 3A</xref>). The results showed that luciferase activity at Site 2 of <italic>Camk2d</italic>, and at Site 1 of <italic>Nfatc3</italic> and <italic>Ncx1</italic>, which are highly conserved across species, was significantly suppressed by <italic>miR-185</italic>. In the same context, mutations of the target sites in the 3′-UTR completely blocked the inhibitory effects of <italic>miR-185</italic>, suggesting that the identified sites, shown in <xref rid="pone.0122509.g003" ref-type="fig">Figs. 3B-3D</xref>, are the direct target sites for <italic>miR-185</italic> regulation. Other predicted targets, including <italic>Ctf1</italic>, <italic>Elk1</italic>, and <italic>Mtpn</italic>, were false positives (Figure H in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>). Collectively, our results suggest that <italic>miR-185</italic> have multiple targets in the Ca<sup>2+</sup>-dependent cardiac hypertrophy signaling pathway.</p>
<fig id="pone.0122509.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g003</object-id>
<label>Fig 3</label>
<caption>
<title><italic>miR-185</italic> directly targets 3′-UTR of <italic>Camk2d</italic>, <italic>Ncx1</italic>, and <italic>Nfatc3</italic>.</title>
<p>(A) Schematic diagram of the pmirGLO chimeric vector indicating where the exact complement target sequences for <italic>miR-185</italic> or mutant sequences were cloned into the 3′-UTR of the luciferase gene. (B-D) The relative positions of predicted binding sites for mouse <italic>miR-185</italic> in the 3′-UTR of the target mRNAs (upper) and quantitative analysis of luciferase activity of the reporter constructs (bottom). HEK-293 cells were transfected with <italic>miR-185</italic> in addition to the reporter constructs with WT or mutated 3′-UTR. After 72 h following transfection, cells were lysed for dual luciferase assay. Hsa, human; Mmu, mouse; Rno, rat; Ptr, chimpanzee. Data represent the mean ± SEM; **<italic>P</italic> &lt; 0.001, or NS (not significant), N = 3.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g003" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec016">
<title><italic>miR-185</italic> regulates NFAT activity <italic>in vitro</italic></title>
<p>Based on evidence concerning the regulation of calcineurin-NFAT signaling by <italic>miR-185</italic> (<xref rid="pone.0122509.g003" ref-type="fig">Fig. 3C</xref>, Figures B and J in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>), we further examined whether inhibition of <italic>miR-185</italic> could activate calcineurin-dependent NFAT transcription factor by luciferase reporter assay employing a reporter under transcriptional control of nine NFAT binding sites (<xref rid="pone.0122509.g004" ref-type="fig">Fig. 4A</xref>). Transfection of NRVMs with <italic>miR-185</italic> inhibitor led to marked induction of the NFAT-dependent luciferase activity compared with the controls for the basal state and for the ET-1 stimulation (<xref rid="pone.0122509.g004" ref-type="fig">Fig. 4B</xref>). In contrast, overexpression of <italic>miR-185</italic> significantly induced phosphorylation of NFATC3, while significantly decreasing the total NFATC3, as assessed by western blotting (<xref rid="pone.0122509.g004" ref-type="fig">Fig. 4C</xref>), suggesting that <italic>miR-185</italic> negatively regulates calcineurin-NFAT signaling.</p>
<fig id="pone.0122509.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g004</object-id>
<label>Fig 4</label>
<caption>
<title><italic>miR-185</italic> negatively regulates NFAT activity in NRVMs.</title>
<p>(A) Schematic representation of the luciferase reporter construct driven by nine tandem NFAT binding sites. (B) Relative luciferase activity in NRVMs transfected with NC or <italic>miR-185</italic> inhibitor. NRVMs were stimulated by ET-1 (10 nmol/L) for 24 h. pRL-TK was transfected for normalization and as an internal control for transfection efficiency. (C) 72 h after transfection of NC or <italic>miR-185</italic> mimic, the level of p-NFATC3 and total NFATC3 were analyzed by western blotting. α-tubulin was used as a loading control. Representative western blots (left) and quantified western blots (right). The data are expressed as mean ± SEM of more than three independent experiments; *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g004" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title><italic>miR-185</italic> modulates CaMKIIδ activity <italic>in vitro</italic></title>
<p>Binding of Ca<sup>2+</sup>/calmodulin to the regulatory domain leads activates CaMKIIδ, and the activated enzyme is subsequently autophosphorylated at Thr-286/287, rendering the kinase constitutively active [<xref rid="pone.0122509.ref027" ref-type="bibr">27</xref>]. Based on our identification of <italic>Camk2d</italic> as a target of <italic>miR-185</italic> (<xref rid="pone.0122509.g003" ref-type="fig">Fig. 3B</xref>), we performed western blotting to examine the level of p-CaMKIIδ after transfection of <italic>miR-185</italic> mimic or <italic>miR-185</italic> inhibitor. As expected, the levels of CaMKIIδ phosphorylation at Thr-286 and total CaMKIIδ were significantly lower in <italic>miR-185</italic>-overexpressing cardiomyocytes compared with the levels in the control group (<xref rid="pone.0122509.g005" ref-type="fig">Fig. 5A</xref>), while inhibition of <italic>miR-185</italic> significantly up-regulated phosphorylation of CaMKIIδ at Thr-286 and the amount of total CaMKIIδ (<xref rid="pone.0122509.g005" ref-type="fig">Fig. 5B</xref>).</p>
<fig id="pone.0122509.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g005</object-id>
<label>Fig 5</label>
<caption>
<title><italic>miR-185</italic> negatively regulates the activity of CaMKIIδ in NRVMs.</title>
<p>(A and B) 72 h after transfection of <italic>miR-185</italic> mimic or <italic>miR-185</italic> inhibitor, the level of p-CaMKIIδ and total CaMKIIδ were analyzed by western blotting. GAPDH was used as a loading control. (C) Western blotting showing p-PLB (Thr-17) and PLB protein expression in NRVMs transfected with NC or <italic>miR-185</italic>. 24 h after transfection, NRVMs were stimulated with ET-1 (10 nmol/L) for 48 h. The blots were stripped for 30 min and reprobed with PLB for loading control. The data are expressed as mean ± SEM; *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.001, N = 3.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g005" position="float" xlink:type="simple"/>
</fig>
<p>Since Thr-17 and Ser-16 of phospholamban (PLB) are independently phosphorylated by CaMKIIδ and cAMP-dependent protein kinase (PKA), respectively [<xref rid="pone.0122509.ref028" ref-type="bibr">28</xref>], we assessed phosphorylation of PLB at Thr-17 as an index of endogenous CaMKIIδ activity in NRVMs after transfection of <italic>miR-185</italic> mimic or NC mimic. Consistent with the change in CaMKIIδ autophosphorylation at Thr-286, overexpression of <italic>miR-185</italic> significantly reduced phosphorylation of PLB at Thr-17 compared with control group (<xref rid="pone.0122509.g005" ref-type="fig">Fig. 5C</xref>), demonstrating that <italic>miR-185</italic> is directly involved in the modulation of the CaMKIIδ activity.</p>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Discussion</title>
<p>Cardiac hypertrophy is a complex gene regulatory disorder that involves aberrant expression of coding mRNAs and regulatory non-coding RNAs. Among the noncoding RNAs, miRNA is the most widely studied one. It is now generally accepted that miRNAs often regulate multiple transcripts in the same biological processes [<xref rid="pone.0122509.ref008" ref-type="bibr">8</xref>]. However, the traditional approach has mostly focused on the identification of a single target for the specific miRNAs in different tissues. In the present study, we used cardiac tissue specific GSA to identify the critical miRNAs and their multiple targets involved in cardiac hypertrophy. Among the 18 GSA-identified cardiac hypertrophy-associated miRNAs, we selected <italic>miR-185</italic> for further studies. We found that <italic>miR-185</italic> plays an important anti-hypertrophic role in the heart and it has three major targets involved in the hypertrophic processes such as <italic>Ncx1</italic>, <italic>Nfatc3</italic>, and <italic>Camk2d</italic> (<xref rid="pone.0122509.g006" ref-type="fig">Fig. 6</xref>).</p>
<fig id="pone.0122509.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0122509.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Working model illustrating the multiple targets of <italic>miR-185</italic> in the calcium-dependent cardiac hypertrophy signaling pathway.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0122509.g006" position="float" xlink:type="simple"/>
</fig>
<p>NCX1 is a bidirectional transporter controlled by membrane potentials and Na<sup>+</sup> and Ca<sup>2+</sup> gradients across plasma membrane [<xref rid="pone.0122509.ref029" ref-type="bibr">29</xref>]. At physiological condition in the heart, NCX1 is the major exchanger by which Ca<sup>2+</sup> is extruded from the cell. Under pathological conditions such as cardiac hypertrophy [<xref rid="pone.0122509.ref030" ref-type="bibr">30</xref>] and ischemic/reperfusion injury [<xref rid="pone.0122509.ref031" ref-type="bibr">31</xref>], however, NCX1 predominantly function in reverse mode due mainly to the elevated [Na<sup>+</sup>]<sub>i</sub> [<xref rid="pone.0122509.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0122509.ref033" ref-type="bibr">33</xref>], mediating Ca<sup>2+</sup> influx. Increased expression of the exchanger has been well documented in human and mouse models of hypertrophy and heart failure [<xref rid="pone.0122509.ref034" ref-type="bibr">34</xref>–<xref rid="pone.0122509.ref036" ref-type="bibr">36</xref>] and NCX1 transgenic mice exhibited hypertrophy and heart failure [<xref rid="pone.0122509.ref037" ref-type="bibr">37</xref>], suggesting the significant correlation between elevation of the NCX1 expression and the magnitude of cardiac pathology. Recently, evidence showed that both genetic ablation [<xref rid="pone.0122509.ref031" ref-type="bibr">31</xref>] and pharmacological inhibition [<xref rid="pone.0122509.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0122509.ref039" ref-type="bibr">39</xref>] of NCX1 can have cardioprotective effects possibly due to prevention of the excessive Ca<sup>2+</sup> overload by inhibiting the reverse mode. miRNAs such as <italic>miR-1</italic> [<xref rid="pone.0122509.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0122509.ref041" ref-type="bibr">41</xref>] and <italic>miR-214</italic> [<xref rid="pone.0122509.ref042" ref-type="bibr">42</xref>], display anti-hypertrophic or cardioprotective effects by directly targeting 3′-UTR of <italic>Ncx1</italic>. Similar to the studies described above, in our studies <italic>miR-185</italic> blunted cardiomyocyte hypertrophy (<xref rid="pone.0122509.g001" ref-type="fig">Figs. 1A-1D</xref>). Inhibition of NCX1 by 1 μM SEA0400 (2-[4-[(2,5-difluorophenyl) methoxy] phenoxy]5-ethoxyaniline), a potent NCX1 inhibitor [<xref rid="pone.0122509.ref043" ref-type="bibr">43</xref>], also reduced cardiomyocyte size and expression of the hypertrophic markers, <italic>ANF</italic> and <italic>BNP</italic>, to a similar extent (Figure I in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>), demonstrating that anti-hypertrophic effect of <italic>miR-185</italic> is due, in part, to repression of <italic>Ncx1</italic>.</p>
<p>Calcineurin-NFAT signaling [<xref rid="pone.0122509.ref044" ref-type="bibr">44</xref>–<xref rid="pone.0122509.ref046" ref-type="bibr">46</xref>] and CaMK [<xref rid="pone.0122509.ref044" ref-type="bibr">44</xref>] signaling are the well-known Ca<sup>2+</sup>-dependent pathways. Among the five members of NFAT family, NFATc3 is an essential downstream effector of calcineurin-regulated cardiac hypertrophy [<xref rid="pone.0122509.ref047" ref-type="bibr">47</xref>]. CaMKII is a multifunctional protein kinase that has been implicated in cardiac hypertrophy and heart failure [<xref rid="pone.0122509.ref048" ref-type="bibr">48</xref>]. Among four isoforms (α, β, δ and γ) of CaMKIIs, CaMKIIδ is the predominant form in the heart [<xref rid="pone.0122509.ref049" ref-type="bibr">49</xref>]. Overexpression of CaMKIIδ induced pathological cardiac hypertrophy and dilated cardiomyopathy [<xref rid="pone.0122509.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0122509.ref051" ref-type="bibr">51</xref>], while CaMKIIδ-null mice prevents cardiac hypertrophy and fibrosis in the aortic-constriction model [<xref rid="pone.0122509.ref052" ref-type="bibr">52</xref>]. CaMKII exerts its effect on cardiac hypertrophy through selective phosphorylation of class II histone deacetylase 4 (HDAC4) and the subsequent activation of MEF2, which is sufficient to promote hypertrophic gene expression [<xref rid="pone.0122509.ref053" ref-type="bibr">53</xref>]. In the present study, we demonstrated that <italic>miR-185</italic> leads to inhibition of these Ca<sup>2+</sup>-activated hypertrophic pathways by simultaneously targeting <italic>Camk2d</italic> and <italic>Nfatc3</italic> and the reduction of their activities.</p>
<p>Our cardiac-specific GSA recapitulated the previously known miRNA-pathways, including <italic>miR-486</italic> in PI3K-Akt signaling (<italic>p</italic>-value: 1.59E-03) [<xref rid="pone.0122509.ref024" ref-type="bibr">24</xref>], <italic>miR-17–92</italic> in TGF-β signaling (<italic>p</italic>-value: 6.34E-03) [<xref rid="pone.0122509.ref054" ref-type="bibr">54</xref>] and <italic>miR-378</italic> in MAPK signaling (<italic>p</italic>-value: 1.76E-02; <xref rid="pone.0122509.s003" ref-type="supplementary-material">S2 Table</xref>) [<xref rid="pone.0122509.ref009" ref-type="bibr">9</xref>]. With regard to <italic>miR-185</italic>, pathways for TGF-β, BAD and VEGF were also predicted to be closely linked to <italic>miR-185</italic> targets (Figure J in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref> and <xref rid="pone.0122509.s003" ref-type="supplementary-material">S2 Table</xref>), implying that <italic>miR-185</italic> may also affect multiple signal transductions in the heart and may play additional roles in cardiac pathogenesis. These novel miRNA-pathway associations and multiple predicted targets shown in <xref rid="pone.0122509.s003" ref-type="supplementary-material">S2 Table</xref> will be further investigated.</p>
<p>The 3′-UTR of mRNA can be bound by multiple miRNAs that may in turn bring about synergistic repression of the target mRNA. In the cardiac hypertrophy signaling network (Figure C in <xref rid="pone.0122509.s001" ref-type="supplementary-material">S1 File</xref>), we also found a high degree of miRNA co-targeting to a single gene, supported by previous findings. For example, it has been reported that <italic>Igf1r</italic> is a target of <italic>miR-1</italic> [<xref rid="pone.0122509.ref055" ref-type="bibr">55</xref>], <italic>miR-139</italic> [<xref rid="pone.0122509.ref056" ref-type="bibr">56</xref>], <italic>miR-378</italic> [<xref rid="pone.0122509.ref057" ref-type="bibr">57</xref>], <italic>miR-99a</italic> [<xref rid="pone.0122509.ref058" ref-type="bibr">58</xref>], and <italic>miR-497</italic> [<xref rid="pone.0122509.ref059" ref-type="bibr">59</xref>]. <italic>Ncx1</italic> has been validated as a target of <italic>miR-1</italic> [<xref rid="pone.0122509.ref040" ref-type="bibr">40</xref>] and <italic>miR-214</italic> [<xref rid="pone.0122509.ref042" ref-type="bibr">42</xref>]. <italic>Pten</italic> is directly targeted by <italic>miR-486</italic> [<xref rid="pone.0122509.ref024" ref-type="bibr">24</xref>], <italic>miR-29a</italic> [<xref rid="pone.0122509.ref060" ref-type="bibr">60</xref>], and <italic>miR-141</italic> [<xref rid="pone.0122509.ref061" ref-type="bibr">61</xref>]. These lines of evidence indicate that the cardiac hypertrophy signaling pathway is under tight regulation by multiple miRNAs through redundant targeting.</p>
<p><italic>miR-185</italic> is encoded within an intron of the <italic>Tango2</italic> gene (also known as <italic>T10</italic>) in the 22q11.2 region. DiGeorge/velocardiofacial syndrome, one of the most common human genetic deletion disorders, with a frequency of nearly one in 3,000 children, results from a microdeletion (mostly 3 Mb in size) within the same band [<xref rid="pone.0122509.ref062" ref-type="bibr">62</xref>,<xref rid="pone.0122509.ref063" ref-type="bibr">63</xref>]. It has been reported that nearly three-quarters of the patients have congenital heart disease (CHD), which is a major cause of morbidity and mortality associated with the syndrome. Interestingly, <italic>miR-185</italic> is the most representative down-regulated miRNA, implying that depletion of <italic>miR-185</italic> substantially contributes to the cardiac defects in the syndrome [<xref rid="pone.0122509.ref064" ref-type="bibr">64</xref>].</p>
<p>The previous studies have also identified additional <italic>miR-185</italic> target genes, such as <italic>RhoA</italic>, <italic>Cdc42</italic>, <italic>and Stim1</italic> [<xref rid="pone.0122509.ref065" ref-type="bibr">65</xref>–<xref rid="pone.0122509.ref069" ref-type="bibr">69</xref>], that are pro-hypertrophic in the heart, suggesting further that <italic>miR-185</italic> is a strong anti-hypertrophic miRNA <italic>in vivo</italic> and a potent therapeutic target for cardiac diseases. However, it remains to be seen whether the delivery of <italic>miR-185</italic> or transgenic over-expression of <italic>miR-185</italic> attenuates cardiac hypertrophy <italic>in vivo</italic>.</p>
<p>In conclusion, the present study shows novel evidence that <italic>miR-185</italic> acts as a key regulator of cardiac hypertrophy by targeting three major genes involved in Ca<sup>2+</sup>-associated pathological hypertrophy.</p>
</sec>
<sec id="sec019">
<title>Supporting Information</title>
<supplementary-material id="pone.0122509.s001" xlink:href="info:doi/10.1371/journal.pone.0122509.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>Supplementary Figures and Tables.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0122509.s002" xlink:href="info:doi/10.1371/journal.pone.0122509.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Heart-expressed miRNAs and mRNAs.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0122509.s003" xlink:href="info:doi/10.1371/journal.pone.0122509.s003" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Complete list of miRNA-function associations and predicted miRNA targets in the gene sets.</title>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Ms. Eun Hee Park for her technical assistance in preparing the animal models.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0122509.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Frey</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>EN</given-names></name>. <article-title>Cardiac hypertrophy: the good, the bad, and the ugly</article-title>. <source>Annu Rev Physiol</source>. <year>2003</year>;<volume>65</volume>: <fpage>45</fpage>–<lpage>79</lpage>. <object-id pub-id-type="pmid">12524460</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gladka</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>da Costa Martins</surname> <given-names>P a</given-names></name>, <name name-style="western"><surname>De Windt</surname> <given-names>LJ</given-names></name>. <article-title>Small changes can make a big difference—microRNA regulation of cardiac hypertrophy</article-title>. <source>J Mol Cell Cardiol</source>. <year>2012</year>;<volume>52</volume>: <fpage>74</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2011.09.015" xlink:type="simple">10.1016/j.yjmcc.2011.09.015</ext-link></comment> <object-id pub-id-type="pmid">21971075</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ding</surname> <given-names>S-L</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>L-Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>P-F</given-names></name>. <article-title>MicroRNAs in cardiac hypertrophy: angels or devils</article-title>. <source>Wiley Interdiscip Rev RNA</source>. <year>2011</year>;<volume>2</volume>: <fpage>124</fpage>–<lpage>134</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/wrna.61" xlink:type="simple">10.1002/wrna.61</ext-link></comment> <object-id pub-id-type="pmid">21956973</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leite-Moreira</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Lourenço</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Falcão-Pires</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Leite-Moreira</surname> <given-names>AF</given-names></name>. <article-title>Pivotal role of microRNAs in cardiac physiology and heart failure</article-title>. <source>Drug Discov Today</source>. <year>2013</year>;<volume>18</volume>: <fpage>1243</fpage>–<lpage>1249</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.drudis.2013.07.025" xlink:type="simple">10.1016/j.drudis.2013.07.025</ext-link></comment> <object-id pub-id-type="pmid">23954179</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Komuro</surname> <given-names>I</given-names></name>. <article-title>Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure</article-title>. <source>Circ J</source>. <year>2008</year>;<volume>72</volume> <issue>Suppl A</issue>: <fpage>A13</fpage>–<lpage>A16</lpage>. <object-id pub-id-type="pmid">18772527</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barry</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Townsend</surname> <given-names>PA</given-names></name>. <article-title>Molecular regulation of cardiac hypertrophy</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2008</year>;<volume>40</volume>: <fpage>2023</fpage>–<lpage>2039</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.biocel.2008.02.020" xlink:type="simple">10.1016/j.biocel.2008.02.020</ext-link></comment> <object-id pub-id-type="pmid">18407781</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartel</surname> <given-names>DP</given-names></name>. <article-title>MicroRNAs: target recognition and regulatory functions</article-title>. <source>Cell</source>. <year>2009</year>;<volume>136</volume>: <fpage>215</fpage>–<lpage>233</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2009.01.002" xlink:type="simple">10.1016/j.cell.2009.01.002</ext-link></comment> <object-id pub-id-type="pmid">19167326</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Small</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>EN</given-names></name>. <article-title>Pervasive roles of microRNAs in cardiovascular biology</article-title>. <source>Nature</source>. <year>2011</year>;<volume>469</volume>: <fpage>336</fpage>–<lpage>342</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature09783" xlink:type="simple">10.1038/nature09783</ext-link></comment> <object-id pub-id-type="pmid">21248840</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganesan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ramanujam</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sassi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ahles</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jentzsch</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Werfel</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>127</volume>: <fpage>2097</fpage>–<lpage>2106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000882" xlink:type="simple">10.1161/CIRCULATIONAHA.112.000882</ext-link></comment> <object-id pub-id-type="pmid">23625957</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Castaldi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zaglia</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Di Mauro</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Carullo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Viggiani</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Borile</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>MiR-133 Modulates the β1Adrenergic Receptor Transduction Cascade</article-title>. <source>Circ Res</source>. <year>2014</year>;<volume>115</volume>: <fpage>273</fpage>–<lpage>283</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.115.303252" xlink:type="simple">10.1161/CIRCRESAHA.115.303252</ext-link></comment> <object-id pub-id-type="pmid">24807785</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Van Rooij</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sutherland</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Williams</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>McAnally</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gerard</surname> <given-names>RD</given-names></name>, <etal>et al</etal>. <article-title>A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>: <fpage>18255</fpage>–<lpage>18260</lpage>. <object-id pub-id-type="pmid">17108080</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cheng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ji</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Yue</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?</article-title> <source>Am J Pathol</source>. <year>2007</year>;<volume>170</volume>: <fpage>1831</fpage>–<lpage>1840</lpage>. <object-id pub-id-type="pmid">17525252</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cha</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility</article-title>. <source>J Mol Cell Cardiol</source>. <year>2008</year>;<volume>45</volume>: <fpage>796</fpage>–<lpage>803</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2008.09.124" xlink:type="simple">10.1016/j.yjmcc.2008.09.124</ext-link></comment> <object-id pub-id-type="pmid">18929570</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Song</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Ryu</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DH</given-names></name>. <article-title>The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1</article-title>. <source>Biochem J</source>. <year>2014</year>;<volume>457</volume>: <fpage>151</fpage>–<lpage>162</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20130833" xlink:type="simple">10.1042/BJ20130833</ext-link></comment> <object-id pub-id-type="pmid">24117217</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>MiR-221 Promotes Cardiac Hypertrophy In vitro Through the Modulation of p27 Expression</article-title>. <source>J Cell Biochem</source>. <year>2012</year>;<volume>113</volume>: <fpage>2040</fpage>–<lpage>2046</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcb.24075" xlink:type="simple">10.1002/jcb.24075</ext-link></comment> <object-id pub-id-type="pmid">22275134</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Da Costa Martins</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Salic</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Gladka</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Armand</surname> <given-names>A-S</given-names></name>, <name name-style="western"><surname>Leptidis</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>El Azzouzi</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling</article-title>. <source>Nat Cell Biol</source>. <year>2010</year>;<volume>12</volume>: <fpage>1220</fpage>–<lpage>1227</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncb2126" xlink:type="simple">10.1038/ncb2126</ext-link></comment> <object-id pub-id-type="pmid">21102440</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Song</surname> <given-names>X-W</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X-C</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>D-F</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>G-K</given-names></name>, <etal>et al</etal>. <article-title>MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes</article-title>. <source>J Cell Physiol</source>. <year>2010</year>;<volume>225</volume>: <fpage>437</fpage>–<lpage>443</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcp.22217" xlink:type="simple">10.1002/jcp.22217</ext-link></comment> <object-id pub-id-type="pmid">20458739</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice</article-title>. <source>Cell Res</source>. <year>2012</year>;<volume>22</volume>: <fpage>516</fpage>–<lpage>527</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/cr.2011.132" xlink:type="simple">10.1038/cr.2011.132</ext-link></comment> <object-id pub-id-type="pmid">21844895</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bernardo</surname> <given-names>BC</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>X-M</given-names></name>, <name name-style="western"><surname>Winbanks</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Boey</surname> <given-names>EJH</given-names></name>, <name name-style="western"><surname>Tham</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Kiriazis</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>: <fpage>17615</fpage>–<lpage>17620</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1206432109" xlink:type="simple">10.1073/pnas.1206432109</ext-link></comment> <object-id pub-id-type="pmid">23047694</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Da Costa Martins</surname> <given-names>P a</given-names></name>, <name name-style="western"><surname>De Windt</surname> <given-names>LJ</given-names></name>. <article-title>MicroRNAs in control of cardiac hypertrophy</article-title>. <source>Cardiovasc Res</source>. <year>2012</year>;<volume>93</volume>: <fpage>563</fpage>–<lpage>572</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvs013" xlink:type="simple">10.1093/cvr/cvs013</ext-link></comment> <object-id pub-id-type="pmid">22266752</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yaosheng</surname> <given-names>Wang</given-names></name>, <name name-style="western"><surname>Xiaoshu</surname> <given-names>Cheng</given-names></name>, <name name-style="western"><surname>Kui</surname> <given-names>Hong</given-names></name>, <name name-style="western"><surname>Yanging</surname> <given-names>Wu</given-names></name>, <name name-style="western"><surname>Wu Qinghua</surname> <given-names>SH</given-names></name>. <article-title>MicroRNA-223 prevents cardiomyocyte hypertrophy by targeting cardiac troponin-I-interacting kinase</article-title>. <source>Heart</source>. <year>2011</year>;<volume>97</volume>: <fpage>A49</fpage>–<lpage>A51</lpage>.</mixed-citation></ref>
<ref id="pone.0122509.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ikeda</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bejar</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bodyak</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes</article-title>. <source>Mol Cell Biol</source>. <year>2009</year>;<volume>29</volume>: <fpage>2193</fpage>–<lpage>2204</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.01222-08" xlink:type="simple">10.1128/MCB.01222-08</ext-link></comment> <object-id pub-id-type="pmid">19188439</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction</article-title>. <source>J Cell Mol Med</source>. <year>2014</year>;<volume>18</volume>: <fpage>919</fpage>–<lpage>928</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jcmm.12242" xlink:type="simple">10.1111/jcmm.12242</ext-link></comment> <object-id pub-id-type="pmid">24628978</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Small</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>O’Rourke</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Moresi</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Sutherland</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>McAnally</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gerard</surname> <given-names>RD</given-names></name>, <etal>et al</etal>. <article-title>Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year>;<volume>107</volume>: <fpage>4218</fpage>–<lpage>4223</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1000300107" xlink:type="simple">10.1073/pnas.1000300107</ext-link></comment> <object-id pub-id-type="pmid">20142475</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alexander</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Casar</surname> <given-names>J</given-names></name>. <article-title>MicroRNA-486–dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy–associated symptoms</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>: <fpage>2651</fpage>–<lpage>2667</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI73579" xlink:type="simple">10.1172/JCI73579</ext-link></comment> <object-id pub-id-type="pmid">24789910</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Belkaya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Murray</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Eitson</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>de la Morena</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Forman</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>van Oers</surname> <given-names>NS</given-names></name>. <article-title>Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1</article-title>. <source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>: <fpage>30752</fpage>–<lpage>30762</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M113.503532" xlink:type="simple">10.1074/jbc.M113.503532</ext-link></comment> <object-id pub-id-type="pmid">24014023</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anderson</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Bers</surname> <given-names>DM</given-names></name>. <article-title>CaMKII in myocardial hypertrophy and heart failure</article-title>. <source>J Mol Cell Cardiol</source>. <year>2011</year>;<volume>51</volume>: <fpage>468</fpage>–<lpage>473</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2011.01.012" xlink:type="simple">10.1016/j.yjmcc.2011.01.012</ext-link></comment> <object-id pub-id-type="pmid">21276796</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hagemann</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kuschel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kuramochi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>R-P</given-names></name>. <article-title>Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes</article-title>. <source>J Biol Chem</source>. <year>2000</year>;<volume>275</volume>: <fpage>22532</fpage>–<lpage>22536</lpage>. <object-id pub-id-type="pmid">10825152</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shigekawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Iwamoto</surname> <given-names>T</given-names></name>. <article-title>Cardiac Na<sup>+</sup>-Ca<sup>2+</sup> Exchange: Molecular and Pharmacological Aspects</article-title>. <source>Circ Res</source>. <year>2001</year>;<volume>88</volume>: <fpage>864</fpage>–<lpage>876</lpage>. <object-id pub-id-type="pmid">11348995</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dulce</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Hurtado</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ennis</surname> <given-names>IL</given-names></name>, <name name-style="western"><surname>Garciarena</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Alvarez</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Caldiz</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Endothelin-1 induced hypertrophic effect in neonatal rat cardiomyocytes: involvement of Na<sup>+</sup>/H<sup>+</sup> and Na<sup>+</sup>/Ca<sup>2+</sup> exchangers</article-title>. <source>J Mol Cell Cardiol</source>. <year>2006</year>;<volume>41</volume>: <fpage>807</fpage>–<lpage>815</lpage>. <object-id pub-id-type="pmid">16859700</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Imahashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Pott</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Goldhaber</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Steenbergen</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Philipson</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Murphy</surname> <given-names>E</given-names></name>. <article-title>Cardiac-specific ablation of the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger confers protection against ischemia/reperfusion injury</article-title>. <source>Circ Res</source>. <year>2005</year>;<volume>97</volume>: <fpage>916</fpage>–<lpage>921</lpage>. <object-id pub-id-type="pmid">16179590</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gray</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>McIntyre</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sheridan</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Fry</surname> <given-names>CH</given-names></name>. <article-title>Intracellular sodium and contractile function in hypertrophied human and guinea-pig myocardium</article-title>. <source>Pflügers Arch</source>. <year>2001</year>;<volume>442</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</mixed-citation></ref>
<ref id="pone.0122509.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Verdonck</surname> <given-names>F</given-names></name>. <article-title>Increased Na<sup>+</sup> concentration and altered Na/K pump activity in hypertrophied canine ventricular cells</article-title>. <source>Cardiovasc Res</source>. <year>2003</year>;<volume>57</volume>: <fpage>1035</fpage>–<lpage>1043</lpage>. <object-id pub-id-type="pmid">12650881</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lu</surname> <given-names>Y-M</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shioda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Fukunaga</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Shirasaki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>XM</given-names></name>, <etal>et al</etal>. <article-title>CaMKIIδB mediates aberrant NCX1 expression and the imbalance of NCX1/SERCA in transverse aortic constriction-induced failing heart</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>: <fpage>e24724</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0024724" xlink:type="simple">10.1371/journal.pone.0024724</ext-link></comment> <object-id pub-id-type="pmid">21931829</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Nolan</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kutschke</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>JA</given-names></name>. <article-title>Na<sup>+</sup>-Ca<sup>2+</sup> exchanger remodeling in pressure overload cardiac hypertrophy</article-title>. <source>J Biol Chem</source>. <year>2001</year>;<volume>276</volume>: <fpage>17706</fpage>–<lpage>17711</lpage>. <object-id pub-id-type="pmid">11279089</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Studer</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Reinecke</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bilger</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Eschenhagen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Bohm</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hasenfuss</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Gene expression of the cardiac Na<sup>+</sup>-Ca<sup>2+</sup> exchanger in end-stage human heart failure</article-title>. <source>Circ Res</source>. <year>1994</year>;<volume>75</volume>: <fpage>443</fpage>–<lpage>453</lpage>. <object-id pub-id-type="pmid">8062418</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roos</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Jordan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fishbein</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ritter</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Friedlander</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>HC</given-names></name>, <etal>et al</etal>. <article-title>Hypertrophy and heart failure in mice overexpressing the cardiac sodium-calcium exchanger</article-title>. <source>Card Fail</source>. <year>2007</year>;<volume>13</volume>: <fpage>318</fpage>–<lpage>329</lpage>. <object-id pub-id-type="pmid">17517353</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Magee</surname> <given-names>WP</given-names></name>, <name name-style="western"><surname>Deshmukh</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Deninno</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Sutt</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Chapman</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Tracey</surname> <given-names>WR</given-names></name>. <article-title>Differing cardioprotective efficacy of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger inhibitors SEA0400 and KB-R7943</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2003</year>;<volume>284</volume>: <fpage>H903</fpage>–<lpage>H910</lpage>. <object-id pub-id-type="pmid">12446284</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Namekata</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Shimada</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Shigenobu</surname> <given-names>K</given-names></name>. <article-title>Cardioprotection without cardiosuppression by SEA0400, a novel inhibitor of Na<sup>+</sup>-Ca<sup>2+</sup> exchanger, during ischemia and reperfusion in guinea-pig myocardium</article-title>. <source>Life Sci</source>. <year>2005</year>;<volume>77</volume>: <fpage>312</fpage>–<lpage>324</lpage>. <object-id pub-id-type="pmid">15878358</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tritsch</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mallat</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lefebvre</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Diguet</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Escoubet</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Blanc</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart</article-title>. <source>Cardiovasc Res</source>. <year>2013</year>;<volume>98</volume>: <fpage>372</fpage>–<lpage>380</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvt042" xlink:type="simple">10.1093/cvr/cvt042</ext-link></comment> <object-id pub-id-type="pmid">23436819</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karakikes</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Chaanine</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mukete</surname> <given-names>BN</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling</article-title>. <source>J Am Heart Assoc</source>. <year>2013</year>;<volume>2</volume>: <fpage>e000078</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/JAHA.113.000078" xlink:type="simple">10.1161/JAHA.113.000078</ext-link></comment> <object-id pub-id-type="pmid">23612897</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aurora</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Mahmoud</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Luo</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Rooij</surname> <given-names>E Van</given-names></name>, <name name-style="western"><surname>Matsuzaki</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca<sup>2+</sup> overload and cell death</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>: <fpage>1222</fpage>–<lpage>1232</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI59327" xlink:type="simple">10.1172/JCI59327</ext-link></comment> <object-id pub-id-type="pmid">22426211</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matsuda</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Arakawa</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Takuma</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kishida</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kawasaki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sakaue</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>SEA0400, a novel and selective inhibitor of the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2001</year>;<volume>298</volume>: <fpage>249</fpage>–<lpage>256</lpage>. <object-id pub-id-type="pmid">11408549</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Molkentin</surname> <given-names>JD</given-names></name>. <article-title>Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs</article-title>. <source>Cardiovasc Res</source>. <year>2004</year>;<volume>63</volume>: <fpage>467</fpage>–<lpage>475</lpage>. <object-id pub-id-type="pmid">15276472</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shimoyama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hayashi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Takimoto</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Zou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Oka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Uozumi</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Calcineurin Plays a Critical Role in Pressure Overload-Induced Cardiac Hypertrophy</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>: <fpage>2449</fpage>–<lpage>2454</lpage>. <object-id pub-id-type="pmid">10595959</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saito</surname> <given-names>T</given-names></name>. <article-title>Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy</article-title>. <source>J Mol Cell Cardiol</source>. <year>2003</year>;<volume>35</volume>: <fpage>1153</fpage>–<lpage>1160</lpage>. <object-id pub-id-type="pmid">12967638</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilkins</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Windt</surname> <given-names>LJ De</given-names></name>, <name name-style="western"><surname>Bueno</surname> <given-names>OF</given-names></name>, <name name-style="western"><surname>Braz</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Glascock</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Kimball</surname> <given-names>TF</given-names></name>, <etal>et al</etal>. <article-title>Targeted disruption of NFATc3, but Not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth</article-title>. <source>Mol Cell Biol</source>. <year>2002</year>;<volume>22</volume>: <fpage>7603</fpage>–<lpage>7613</lpage>. <object-id pub-id-type="pmid">12370307</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ling</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Pereira</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Means</surname> <given-names>CK</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Requirement for Ca<sup>2+</sup>/ calmodulin–dependent kinase II in the transition from pressure overload–induced cardiac hypertrophy to heart failure in mice</article-title>. <source>J Clin Invest</source>. <year>2009</year>;<volume>119</volume>: <fpage>1230</fpage>–<lpage>1240</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI38022" xlink:type="simple">10.1172/JCI38022</ext-link></comment> <object-id pub-id-type="pmid">19381018</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anderson</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Heller</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bers</surname> <given-names>DM</given-names></name>. <article-title>Journal of Molecular and Cellular Cardiology CaMKII in myocardial hypertrophy and heart failure</article-title>. <source>J Mol Cell Cardiol</source>. <year>2011</year>;<volume>51</volume>: <fpage>468</fpage>–<lpage>473</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2011.01.012" xlink:type="simple">10.1016/j.yjmcc.2011.01.012</ext-link></comment> <object-id pub-id-type="pmid">21276796</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>EN</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Morissette</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>VP</given-names></name>, <name name-style="western"><surname>Gigena</surname> <given-names>MS</given-names></name>, <etal>et al</etal>. <article-title>The cardiac-specific nuclear delta(B) isoform of Ca<sup>2+</sup>/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity</article-title>. <source>J Biol Chem</source>. <year>2002</year>;<volume>277</volume>: <fpage>1261</fpage>–<lpage>1267</lpage>. <object-id pub-id-type="pmid">11694533</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Maier</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Dalton</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Miyamoto</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>J</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Bers</surname> <given-names>DM</given-names></name>, <etal>et al</etal>. <article-title>The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure</article-title>. <source>Circ Res</source>. <year>2003</year>;<volume>92</volume>: <fpage>912</fpage>–<lpage>919</lpage>. <object-id pub-id-type="pmid">12676814</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Backs</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Backs</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Neef</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kreusser</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Lehmann</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Patrick</surname> <given-names>DM</given-names></name>, <etal>et al</etal>. <article-title>The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>: <fpage>2342</fpage>–<lpage>2347</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0813013106" xlink:type="simple">10.1073/pnas.0813013106</ext-link></comment> <object-id pub-id-type="pmid">19179290</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Backs</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bezprozvannaya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>EN</given-names></name>. <article-title>CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</article-title>. <source>J Clin Invest</source>. <year>2006</year>;<volume>116</volume>: <fpage>1853</fpage>–<lpage>1864</lpage>. <object-id pub-id-type="pmid">16767219</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mestdagh</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bostrom</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Impens</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Fredlund</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Van Peer</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>De Antonellis</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>The miR-17–92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma</article-title>. <source>Mol Cell</source>. <year>2010</year>;<volume>40</volume>: <fpage>762</fpage>–<lpage>773</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molcel.2010.11.038" xlink:type="simple">10.1016/j.molcel.2010.11.038</ext-link></comment> <object-id pub-id-type="pmid">21145484</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elia</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Contu</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Quintavalle</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Varrone</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Chimenti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Russo</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>: <fpage>2377</fpage>–<lpage>2385</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.109.879429" xlink:type="simple">10.1161/CIRCULATIONAHA.109.879429</ext-link></comment> <object-id pub-id-type="pmid">19933931</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yin</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor</article-title>. <source>Biochem Pharmacol</source>. <year>2012</year>;<volume>84</volume>: <fpage>320</fpage>–<lpage>330</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bcp.2012.04.017" xlink:type="simple">10.1016/j.bcp.2012.04.017</ext-link></comment> <object-id pub-id-type="pmid">22580051</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knezevic</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sundaresan</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Gupta</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Solaro</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Nagalingam</surname> <given-names>RS</given-names></name>, <etal>et al</etal>. <article-title>A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>: <fpage>12913</fpage>–<lpage>12926</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M111.331751" xlink:type="simple">10.1074/jbc.M111.331751</ext-link></comment> <object-id pub-id-type="pmid">22367207</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lerman</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Avivi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mardoukh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Barzilai</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tessone</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gradus</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>: <fpage>e20916</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0020916" xlink:type="simple">10.1371/journal.pone.0020916</ext-link></comment> <object-id pub-id-type="pmid">21687694</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>W</given-names></name>. <article-title>MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor</article-title>. <source>Surgery</source>. <year>2013</year>;<volume>153</volume>: <fpage>836</fpage>–<lpage>847</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.surg.2012.12.004" xlink:type="simple">10.1016/j.surg.2012.12.004</ext-link></comment> <object-id pub-id-type="pmid">23453369</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>X</given-names></name>. <article-title>Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium</article-title>. <source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>: <fpage>10418</fpage>–<lpage>10426</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M112.444463" xlink:type="simple">10.1074/jbc.M112.444463</ext-link></comment> <object-id pub-id-type="pmid">23426367</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network</article-title>. <source>Carcinogenesis</source>. <year>2010</year>;<volume>31</volume>: <fpage>559</fpage>–<lpage>566</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/carcin/bgp335" xlink:type="simple">10.1093/carcin/bgp335</ext-link></comment> <object-id pub-id-type="pmid">20053927</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kobrynski</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Sullivan</surname> <given-names>KE</given-names></name>. <article-title>Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>: <fpage>1443</fpage>–<lpage>1452</lpage>. <object-id pub-id-type="pmid">17950858</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karayiorgou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Simon</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Gogos</surname> <given-names>JA</given-names></name>. <article-title>22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia</article-title>. <source>Nat Rev Neurosci</source>. <year>2010</year>;<volume>11</volume>: <fpage>402</fpage>–<lpage>416</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrn2841" xlink:type="simple">10.1038/nrn2841</ext-link></comment> <object-id pub-id-type="pmid">20485365</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De la Morena</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Eitson</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Dozmorov</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Belkaya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hoover</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Anguiano</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome</article-title>. <source>Clin Immunol</source>. <year>2013</year>;<volume>147</volume>: <fpage>11</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clim.2013.01.011" xlink:type="simple">10.1016/j.clim.2013.01.011</ext-link></comment> <object-id pub-id-type="pmid">23454892</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells</article-title>. <source>Cancer Lett</source>. <year>2011</year>;<volume>301</volume>: <fpage>151</fpage>–<lpage>160</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2010.11.009" xlink:type="simple">10.1016/j.canlet.2010.11.009</ext-link></comment> <object-id pub-id-type="pmid">21186079</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Del Re</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Sussman</surname> <given-names>MA</given-names></name>. <article-title>The Rac and Rho hall of fame: a decade of hypertrophic signaling hits</article-title>. <source>Circ Res</source>. <year>2006</year>;<volume>98</volume>: <fpage>730</fpage>–<lpage>742</lpage>. <object-id pub-id-type="pmid">16574914</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carè</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Catalucci</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Felicetti</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bonci</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Addario</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gallo</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-133 controls cardiac hypertrophy</article-title>. <source>Nat Med</source>. <year>2007</year>;<volume>13</volume>: <fpage>613</fpage>–<lpage>618</lpage>. <object-id pub-id-type="pmid">17468766</object-id></mixed-citation></ref>
<ref id="pone.0122509.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Feng</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer</article-title>. <source>Oncogene. In press</source>.</mixed-citation></ref>
<ref id="pone.0122509.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luo</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Hojayev</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z V</given-names></name>, <name name-style="western"><surname>Tandan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rakalin</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>STIM1-dependent store-operated Ca<sup>2+</sup> entry is required for pathological cardiac hypertrophy</article-title>. <source>J Mol Cell Cardiol</source>. <year>2012</year>;<volume>52</volume>: <fpage>136</fpage>–<lpage>147</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2011.11.003" xlink:type="simple">10.1016/j.yjmcc.2011.11.003</ext-link></comment> <object-id pub-id-type="pmid">22108056</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>